An observational, prospective, uncontrolled, and descriptive study in real-world migraine patients treated with monoclonal antibodies
Latest Information Update: 07 Sep 2022
At a glance
- Drugs Erenumab (Primary) ; Fremanezumab (Primary) ; Galcanezumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 07 Sep 2022 New trial record
- 01 Aug 2022 Results published in the Postgraduate Medicine